Amplia Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Amplia Therapeutics has a total shareholder equity of A$14.8M and total debt of A$2.1M, which brings its debt-to-equity ratio to 14.3%. Its total assets and total liabilities are A$17.6M and A$2.8M respectively.
Key information
14.3%
Debt to equity ratio
AU$2.11m
Debt
| Interest coverage ratio | n/a |
| Cash | AU$5.66m |
| Equity | AU$14.75m |
| Total liabilities | AU$2.81m |
| Total assets | AU$17.56m |
Recent financial health updates
We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully
Jan 13
Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth
Apr 28Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth
Jan 06
Recent updates
We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully
Jan 13Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth
Apr 28Amplia Therapeutics Limited (ASX:ATX) Insiders Increased Their Holdings
Feb 28Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth
Jan 06Financial Position Analysis
Short Term Liabilities: ATX's short term assets (A$9.4M) exceed its short term liabilities (A$2.7M).
Long Term Liabilities: ATX's short term assets (A$9.4M) exceed its long term liabilities (A$60.6K).
Debt to Equity History and Analysis
Debt Level: ATX has more cash than its total debt.
Reducing Debt: ATX's debt to equity ratio has increased from 0% to 14.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ATX has sufficient cash runway for 12 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: ATX is forecast to have sufficient cash runway for 11 months based on free cash flow estimates, but has since raised additional capital.